Рандомизированное исследование ESCAPE1: Зокор 20-80 мг у больных с семейной гиперхолестеринемией и ишемической болезнью сердца. Часть 1. Гиполипидемическая эффективность, безопасность и переносимость

Основной целью рандомизированного исследования ESCAPE было изучение гиполипидемической эффективности, переносимости и влияние на сосудистую стенку разных доз симвастатина (20 и 80 мг/сут.) при лечении 50 больных с ишемической болезнью сердца и семейной гиперхолестеринемией (СГХС). Исследование продолжалось 76 недель, и по его результатам лечение симвастатином (Зокор™, MSD) 20 мг в сутки сопровождалось снижением уровня холестерина липопротеидов низкой плотности на 22-30 % по сравнению с исходными значениями, в группе больных, получавших 80 мг Зокора, - на 32,7 %, а в группе больных, получавших 80 мг препарата, - на 44,5 % (р < 0,001 для обеих групп). Длительное лечение симвастатином 20 и 80 мг/сут. у больных с СГХС переносилось хорошо, на протяжении курса лечения серьезных побочных эффектов отмечено не было.

статины, симвастатин, семейная гиперхолестеринемия, липопротеиды низкой плотности, рандомизированное исследование, эффективность

1. Scandinavian Simvastatin Survival Study Group. Randomized I of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S) // Lancet. - 1994. - Vol. 344, № 8934. - P. 1383-1389.

2. Shepherd J., Cobbe S.M., Isles C.G. et al. Prevention of coronary disease with pravastatin in men with hypercholesterolemia // N. Engl. Med. - 1995. - Vol. 333, №20. - P. 1301- 1307.

3. Sacks F.N., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin coronary events after myocardial infarction in patients with average cholesterol level // N. Engl. J. Med. - 1996. - Vol. 335, № 14. - P. 1001-1009.

4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with Pravastatin in ischemic disease (LIPID) Study Group // N. Engl. J. Med. - 1998. - Vol. 339, № 19. - P. 1349-1357.

5. Downs J.R. Clearfield M„ Weis S. et al. for the AFCAPS/TexCAPS Research Group. Primary prevention ofacute coronary events with lovastalin in men and women with average cholesterol levels // JAMA. - 1998. - Vol. 279, № 20. - P. 1615-1622.

6. Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial // Lancet. - 2002. - Vol. 360, № 9346. - P. 1623-1630.

7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic. hypertensive patients randomized to Pravastatin vs usual care. The antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial (ALLHAT-LLT) // JAMA. - 2002. - Vol. 288, № 23. - P. 2898-3007.

8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial // Lancet. - 2002. - Vol. 360, № 9326. - P. 7-22.

9. Pcdersen T.R., Faergeman O., Kaslelein J.J. et al. Design and baseline characteristics of the incremental decrease in end points through aggressive lipid lowering study // Am. J. Cardiol. - 2004. - Vol. 94. № 6. - P. 720-724.

10. Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) // JAMA. - 2001. - Vol. 285, № 19. - P. 2486-2497.

11. Kotseva K., Wood D., de Backer G. et al. Cardiovascular prevention guidelines in a daily practice: a comparison of EUROASPIRE I. II and III surveys in eight European countries // Lancet. - 2009. - Vol. 373, № 9667. - P. 929-940.

12. Ganse E.V., Laforest L., Alemao E. et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the return on expenditure achieved for lipid therapy (REALITY) study // Curr. Med. Res. Opin. 2005. - Vol. 21, № 9. - P. 1389-1399.

13. Nitiyanant W. Sritara P. Deerochanawong С el al. Lipid treatment assessment project II in Thailand (LT'AP II Thailand). // J. Med. Assoc. Thai. - 2008. - Vol. 91, № 6. - P. 836-45.

14. WHO. Human genetic program. Familial hypercholesterolaemia. report of a WHO consultation. WHO/HGN/FH/CONS/98.7 - Paris. - October 1997.

15. Civeira F. International panel on management of familial hypercholesterolaemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia // Atherosclerosis. - 2004. - Vol. 173, № 1. - P. 55-68.

16. Endo A. The discovery and development of HMG-CoA reductase inhibitors // J. Lipid Res. - 1992. - Vol. 33, № 11. - P. 1569-1582.

17. Simons L.A., Sullivan D., Simons J., Celermajer D.S. Effect of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia // Atherosclerosis. - 1998. - Vol. 137, № 1. - P. 197-203.

18. Smildc T.J., van Wissen S., Wollersheim H. et al. Effect of aggressive versus conventional lipid-lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial // Lancet. 2001. - Vol. 357, № 9256. - P. 574-581.

19. Kastelein J., Akdim F., Stroes E. et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia // N. Engl. J. Med. - 2008. - Vol. 358, № 14. - P. 1431-1443.

20. Sussekov A.V., Kulcv В., Zubareva M.Yu. et al. Effect of Simvastatin 20 and 80 mg/day on endothelial function and structure in CHD patients with familial hypercholesterolaemia. Final results of ESCAPE Study // Circulation. - 2006. - Vol. 114, № 18. (Suppl.). - P. II- 318.

21. Kane J.P., Malloy M.J., Ports ТА. et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolaemia with combined drug regimens // JAMA. - 1990. - Vol. 264, № 23. - P. 3007-3012.

22. Tatami R., Inoue N., Itoh H. et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering therapy in patients with familial hypercholesterolaemia: a multicentre study. The LARS Investigators // Atherosclerosis. - 1992. - Vol. 95, № 1. - P. 1-13.

23. Thompson G.R., Mahcr V.M., Mattews S. et al. Familial hypercholesterolemia regression study: a randomized trial of low-density lipoprotein apheresis // Lancet. 1995. - Vol. 345, № 8953. - P. 811-816.

24. Kroon A.A., Aengcvaeren W.R., van der Werf T. et al. LDL-apheresis atherosclerosis regression study (LAARS). Effect of agressive versus conventional lipid-lowering treatment on coronary atherosclerosis // Circulation. - 1996. - Vol. 93, № 10. - P. 1826-1835.

25. Nishimura S., Sekiguchi M., Капо Т. et al. Effects of intensive lipid-lowering by low density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolaemia: Japan low-density lipoprotein apheresis coronary atherosclerosis prospective study (L-CAPS) // Atherosclerosis. - 1999. - Vol. 144, № 2. - P. 409-417.

26. Matsuzaki M., Hiramori K., Imaizumi T. et al. Intravascular evaluation of coronary plaque regression by low density lipoprotein apheresis in familial hypercholesterolemia: the low density lipoprotein apheresis coronary morphology and reserve trial (LACMART)// J. Am. Coll. Cardiol. - 2002. - Vol. 40, № 2. - P. 220-227.

27. Сусеков A.B., Соловьева Е.Ю., Кухарчук В.В. Симвастатин и аторвастатин 80 мг в сутки при лечении больных с наследственной гиперхолестеринемией // Клинич. фармакология и терапия. - 2002. - Т.11, № 3. - С. 12-15.

28. Балахонова Т.В., Погорелова Т.В., Сусеков А.В. и др. Влияние аторвастатина на функциональное состояние эндотелия у больных с наследственной гиперхолестеринемией // Кардиология. - 2002. - № 1.- С. 15-21.

29. Сусеков А.В., Соловьева Е.Ю., Рожкова Т.А. Симвастатин при лечении больных с первичной гиперхолестеринемией: эффективность суточных доз 10-80 мг // Кардиология. - 2002. - Т. 42, № 1. - С. 33-36.

30. Defesche J. Familial hypercholesterolaemia // Lipids and vascular disease / Ed. by.1. Betteridge. - London: Martin Dunitz, 2000. - Vol. 6. - P. 65-76.

31. Ose L., Davidson M.Н., Stein E.A. et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group // Clin. Cardiol. - 2000. - Vol. 23, № 1. - P. 39-46.

32. Davidson M.H., Stein E.A., Hunninghake D.B. et al. for the Worldwide Expanded Dose Simvastatin Study Group. Lipid-altering efficacy and safely of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia // Nutr. Metab. Cardiovasc. Dis. - 2000. - Vol. 10, № 5. - P. 253-262.

33. de Savage Nolting P.R.W., Buirma R.J.A., Mullen B.A. et al. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolaemia (The Examination of probands and relatives in statin studies with familial hypercholesterolaemia [ExPRESS FH]) // Am. J. Cadiol. - 2002. - Vol. 90. № 2. - P. 181-184.

34. Thompson G.R., O'Neil R., Seed M. Why some patients respond poorly to statins and how this might be remedied // Eur. Heart J. - 2002. - Vol. 23, № 3. -P. 200-206.

35. de Sauvage Nolling P.R.W., Buirma R.J.A., lluttcn B.A. et al. Baseline lipid values partly determine the response lo high-dose simvastatin in patients with familial hypercholesterolaemia. The examination of probands and relatives in Statin studies with familial hypercholesterolaemia (ExPRESS FH) // Atherosclerosis. - 2002. - Vol. 164, № 2. - P. 347-354.

36. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia // Am. J. Cardiol. - 1998. - Vol. 81, № 4A. - Р. 66B-69B.

37. Eckardstein A., Assnrann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? // Curr. Opin. Lipidol. 2000. - Vol. 11, № 6. - P. 627-637.

38. Langmann T., Klucken J., Reil M. et al. Molecular cloning of the human ATP binding cassette transporter I (hABC 1): evidence for sterol-dependent regulation in macrophages // Biochem. Biophys. Res. Commun. - 1999. - Vol. 257, № 1. - P. 29-33.

39. Segresl J.P., Li L., Anantharamaiah G.M. et al. Structure and function of apolipoprotein A 1 and high-density lipoprotein // Curr. Opin. Lipidol. - 2000. - Vol. II, № 2. - P. 105-115.

40. Heart Protection Study Collaboartive Group. Effect of cholesterol-lowering with Simvastatin on slroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions // Lancet. - 2004. - Vol. 363, № 9411. - P. 757-767.

41. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20536 high-risk people:a randomised placebo-controlled trial // BMC Medicine. - 2005. - Vol. 3, № 6. - P. 1-21.

42. Grundy S.M., Cleeman J.I., Baircy C.N. et al. Implicalion recent clinical trials for the national cholesterol education program adult treatment panel 111 Guidelines // Circulation. - 2004.- Vol. 110, № 2. - P. 227-239.